Cannabis and ALS (Amyotrophic Lateral Sclerosis)

This article is for information only and is not medical advice. Talk to a doctor before using cannabis for a health condition, and do not stop or change prescribed treatment on your own.

Not Medical Advice

This article is not medical advice. It is an evidence summary for educational use. ALS is a serious, progressive, terminal disease. Do not start, stop, or change any treatment — including cannabis — without talking to a neurologist familiar with motor neuron disease.

Cannabis can interact with medications, affect sedation and respiratory function, and impair cognition — all of which matter enormously in ALS. This article describes what controlled trials and observational evidence show; it does not replace consultation with your medical team.

Plain-Language Summary

Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease that kills motor neurons in the brain and spinal cord, leading to muscle weakness, paralysis, and eventually respiratory failure. Median survival is roughly 3–5 years from symptom onset ^[1]. There is no cure. Approved disease-modifying drugs — riluzole, edaravone, and tofersen (for SOD1-mutation ALS) — extend survival modestly ^[2][3][12].

Cannabis has been proposed for ALS for two main reasons: (1) anecdotal reports that it helps with symptoms like cramps, spasticity, and sleep disruption, and (2) preclinical studies in mice suggesting cannabinoids might be neuroprotective ^[4][9]. Some symptomatic claims have been tested in a controlled trial; the neuroprotection story has not translated to humans.

This article separates what controlled evidence supports from what remains anecdote or extrapolation.

What Probably Works: Spasticity and Related Symptoms

Spasticity. The strongest cannabis-and-neurology evidence comes from multiple sclerosis, where nabiximols (Sativex, a 1:1 THC:CBD oromucosal spray) is approved in many countries for spasticity ^[5]. A randomized controlled trial in ALS patients — CANALS (Riva et al. 2019) — tested nabiximols specifically for spasticity in motor neuron disease and found statistically significant improvement on the Numerical Rating Scale for spasticity versus placebo, with acceptable tolerability Strong evidence ^[6]. This is the single best ALS-specific cannabis trial published to date. The trial was conducted in specialist motor neuron disease clinics across the UK and Europe, involved 24 weeks of treatment, and enrolled 44 patients ^[6]. Nabiximols was used as an add-on to existing antispastic medications (baclofen, tizanidine, etc.), not as a replacement.

Cramps and muscle stiffness. These are often grouped with spasticity in clinical reports and patient surveys. The CANALS trial captured improvements in this domain as well Weak / limited ^[6]. No separate RCT for cramps alone in ALS exists.

Sleep. THC is sedating and shortens sleep onset in the short term ^[7]. Strong evidence No ALS-specific RCT, but sleep is frequently disrupted in ALS by cramps, anxiety, and respiratory distress. Patients commonly report subjective benefit, and short-term THC use for sleep has established evidence in general populations Anecdote.

What Might Work: Weaker and Indirect Evidence

Sialorrhea (excess saliva / drooling). THC has weak anticholinergic-like effects and some clinicians use it adjunctively for this symptom Weak / limited. Evidence is largely anecdotal and case-report level. Standard treatments (glycopyrrolate, atropine drops, botulinum toxin) remain first-line.

Appetite and weight loss. Cachexia is a poor prognostic sign in ALS ^[1]. THC and dronabinol increase appetite in HIV wasting and cancer contexts Weak / limited ^[8]. Extrapolation to ALS is mechanistically reasonable — endocannabinoid tone affects appetite broadly — but has not been directly tested in adequately powered ALS trials Weak / limited.

Pain. Musculoskeletal and neuropathic pain are common in ALS. Cannabis has moderate evidence for chronic pain management in general populations ^[8], but no ALS-specific pain trials exist Weak / limited.

Pseudobulbar affect and anxiety. Anecdotal patient reports exist; no controlled data in ALS populations Anecdote.

What Doesn't Work or Lacks Evidence

Disease modification, neuroprotection, or survival extension. This is critical. SOD1 transgenic mouse studies showed that cannabinoids (Δ9-THC, cannabinol, WIN 55,212-2) modestly delayed disease onset or progression in animals ^[4][9]. Weak / limited This has never been replicated in a human trial. The SOD1 mouse is also a notoriously poor predictor of clinical success; dozens of drugs have worked in the mouse and failed in patients ^[10]. Claims that cannabis 'slows ALS progression' or 'stops ALS' in humans are not supported by evidence. No data

CBD as monotherapy for ALS. No human RCT supports this No data.

'Rick Simpson Oil' or high-dose THC oil as a cure. These claims rely entirely on testimonials, not controlled trials No data.

Extrapolation from MS spasticity trials to ALS disease modification. Even though nabiximols helps MS spasticity, this does not mean cannabis affects ALS progression No data.

What We Don't Know

• Whether cannabinoids meaningfully affect ALS progression in humans (likely not, but never adequately tested in a prospective trial).
• Optimal THC:CBD ratio, dose, and route of administration for each ALS symptom.
• Long-term safety in patients with declining respiratory function — a critical gap. Smoking anything is contraindicated in ALS. Even vaporized THC can increase heart rate and lower blood pressure Weak / limited, which matters for ALS patients with respiratory compromise.
• Interactions with riluzole, edaravone, and tofersen. CBD inhibits CYP3A4 and CYP2C19 enzymes Strong evidence ^[11], and could plausibly alter levels of co-administered drugs Weak / limited — but no outcome data exist in ALS patients specifically No data.
• Whether bulbar-onset patients (who have swallowing and speech difficulty) can safely use oromucosal sprays or whether aspiration risk is unacceptably high.
• Effect on cognitive symptoms. A subset of ALS patients develop frontotemporal cognitive change ^[14]; THC effects in this population are unstudied.

Comparison With Standard ALS Treatments

Disease-modifying drugs. Riluzole extends median survival by roughly 2–3 months ^[2]. Edaravone may slow functional decline in a subset of patients ^[3]. Tofersen targets SOD1-mutation ALS specifically and extends survival modestly ^[12]. Cannabis does not belong in this category — it has no demonstrated effect on survival or on the ALS Functional Rating Scale Revised (ALSFRS-R) progression.

Symptomatic standard of care. Baclofen and tizanidine are first-line for spasticity; quinine sulfate or levetiracetam for cramps; glycopyrrolate, atropine drops, or botulinum toxin for sialorrhea; non-invasive ventilation for respiratory support; and multidisciplinary clinic care, which itself extends survival ^[13]. Cannabis is best understood as a possible add-on for refractory symptoms, not a replacement for any of these.

The CANALS trial positioned nabiximols as adjunctive — added on top of existing antispastic medication — which is the realistic clinical framing ^[6]. Patients in that trial were already on standard antispastic agents and had incomplete symptom control.

Risks and Practical Considerations

Respiratory function. ALS commonly causes diaphragmatic and intercostal weakness. Smoking cannabis is a particularly bad idea. Vaporization, tinctures, oromucosal sprays, and oral edibles are safer routes, though long-term safety data in advanced ALS are absent Weak / limited.

Sedation and falls. THC impairs balance and coordination Strong evidence. ALS patients are already fall-prone due to weakness and ataxia. Start very low and monitor closely.

Cognitive effects. Up to half of ALS patients have some cognitive change, and a smaller subset develop frontotemporal dementia ^[14]. THC can worsen cognitive symptoms in other populations; effects in ALS are unstudied.

Drug interactions. CBD inhibits CYP450 enzymes; speak with a pharmacist to review your full medication list, especially if you take riluzole or other hepatically metabolized drugs Strong evidence ^[11]. See also Cannabis and Polypharmacy Risks.

Cost and access. Pharmaceutical-grade nabiximols is expensive and not available everywhere. Dispensary products vary widely in cannabinoid content and consistency Strong evidence.

Hypotension, tachycardia, and dry mouth. These are common acute side effects of THC. ALS patients with cardiac or autonomic changes should be cautious Strong evidence.

Conservative approach if you decide to try cannabis: A balanced (1:1 THC:CBD) or CBD-dominant product, oromucosal or oral route, very low starting dose, slow titration, and clear target symptoms so you and your clinician can assess whether it is actually helping.

Bottom Line

Cannabis — specifically nabiximols — has moderate evidence for reducing refractory spasticity in ALS as an add-on therapy, based on one well-designed trial. Anecdotal support exists for sleep and cramps. Claims that cannabis modifies ALS disease course or prolongs survival are not supported by evidence and should be treated as marketing folklore. Any use should be adjunctive, monitored by your neurologist, and never in place of proven ALS treatments or respiratory support.

Sources

How this page was made

Related

• Cannabis and Multiple Sclerosis Spasticity — Nabiximols shows consistent patient-reported benefit for resistant MS spasticity; objectiv...
• Cannabis and Nightmares — THC suppresses REM sleep, reducing nightmares acutely, but evidence is strongest for nabil...
• Cannabis and Polypharmacy Risks — How cannabis affects multiple-medication regimens, and which interactions are real.